Tri-Institutional Therapeutics Discovery Institute Announced

VIDEO | 05:00

Memorial Sloan Kettering Cancer Center, The Rockefeller University, and Weill Cornell Medical Collegehave announced that they have formed the pioneering Tri-Institutional Therapeutics Discovery Institute, Inc. (Tri-I TDI) and have partnered with Takeda Pharmaceutical Company, Ltd. (TSE:4502). This new, groundbreaking institute, designed to expedite early-stage drug discovery into innovative treatments and therapies for patients, was founded thanks to a generous $15 million gift by Lewis Sanders and a $5 million gift from Howard and Abby Milstein. “The goal of this new institute is to bring together academics and pharmaceutical company scientists to make the process of moving ideas from the academic institution into useful patient drugs and diagnostic agents,” says David Scheinberg, Chairman of the Molecular Pharmacology Program at Memorial Sloan Kettering Cancer Center.  “This therapeutics discovery institute should help us bridge this gap, make the process faster, and get drugs to patients much more quickly.”